The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S.

WARNING: GRAPHIC CONTENT A grieving husband has claimed his wife died from complications of the Johnson & Johnson COVID-19 ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

Since May 2025, Pfizer (PFE) traded in a narrow range between $24.00 and $26. The company does not have shareholder ...

Economic cost of L.A. wildfires expected to keep rising, Bezos suffers rocket launch setback in space race with Musk, more news to start your day. The Edge specializes in special situations such as ...

Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM ESTCompany ParticipantsMatthew Gline - CEO ...

Joe Gebbia, a co-founder of Airbnb and a Tesla director, just bought $1 million of shares of the electric-vehicle firm. Retailer Dollar Tree is one of the bright spots of the stock market, and Chief ...

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.